Ceritinib vs Ensartinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

Ceritinib

Marketed by Novartis

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01828099 · Phase 3 · completed

The trial was randomized and actively controlled, with 189 patients assigned to ceritinib and 187 to chemotherapy, but treatment was open-label rather than double-blind. Its clinical primary endpoint, progression-free survival assessed by an independent review committee, was met: median progression-free survival was 16.6 versus 8.1 months, with hazard ratio 0.55 (95% CI 0.42–0.73; p<0.001).

Next expected readout: December 2026 · NCT02321501 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1) (met)

Result source: NCT01828099

Ensartinib · Ensacove

Marketed by Xcovery Holdings and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02767804 · Phase 3 · active, not recruiting

This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.

Next expected readout: February 2027 · NCT05241028 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)

Result source: NCT02767804

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCeritinibEnsartinib
PFS, median16.6 vs 8.1vs Chemotherapyn 189NCT01828099
10 other results
—Trial running · NCT06955325
OS, median62.9 vs 40.7vs Chemotherapyn 189NCT01828099
5 other results
—Trial running · NCT06955325
ORR72.5% vs 26.7%vs Chemotherapyn 189NCT01828099
12 other results
—Trial running · NCT06955325
Duration of response, median23.9 vs 11.1vs Chemotherapyn 137NCT01828099
12 other results
—Trial running · NCT06955325

PFS, median

Ceritinib
16.6 vs 8.1vs Chemotherapyn 189NCT01828099
10 other results
Ensartinib
—Trial running · NCT06955325

OS, median

Ceritinib
62.9 vs 40.7vs Chemotherapyn 189NCT01828099
5 other results
Ensartinib
—Trial running · NCT06955325

ORR

Ceritinib
72.5% vs 26.7%vs Chemotherapyn 189NCT01828099
12 other results
Ensartinib
—Trial running · NCT06955325

Duration of response, median

Ceritinib
23.9 vs 11.1vs Chemotherapyn 137NCT01828099
12 other results
Ensartinib
—Trial running · NCT06955325
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ceritinib: 4 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCeritinibEnsartinib
Dropout rate
n/a: no completion milestonea
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
n/a: no completion milestoneCeritinib
NCT01828112 · Phase 3 · monotherapy
—Ceritinib (On-treatment)
NCT01828112 · Phase 3
n/a: no completion milestone750 mg
NCT01283516 · Phase 1
n/a: no completion milestone700 mg
NCT01283516 · Phase 1
n/a: no completion milestone600 mg
NCT01283516 · Phase 1
n/a: no completion milestone500 mg
NCT01283516 · Phase 1
n/a: no completion milestone400 mg
NCT01283516 · Phase 1
n/a: no completion milestone300 mg
NCT01283516 · Phase 1
n/a: no completion milestone200 mg
NCT01283516 · Phase 1
n/a: no completion milestone100 mg
NCT01283516 · Phase 1
n/a: no completion milestone50 mg
NCT01283516 · Phase 1
n/a: no completion milestone
NCT02450903 · Phase 2 · registry result, not featured evidence
74.2%LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT02040870 · Phase 1/2 · registry result, not featured evidence
0%225 mgb
NCT01625234 · Phase 1/2
show 7 more results
0%225 mg
NCT01625234 · Phase 1/2
0%250 mg
NCT01625234 · Phase 1/2
0%200 mg
NCT01625234 · Phase 1/2
0%100 mg
NCT01625234 · Phase 1/2
0%50 mg
NCT01625234 · Phase 1/2
0%25 mg
NCT01625234 · Phase 1/2
n/a: no completion milestone200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
12.7%a
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
6.1%Ceritinib
NCT01828112 · Phase 3 · monotherapy
—Ceritinib (On-treatment)
NCT01828112 · Phase 3
11%750 mg
NCT01283516 · Phase 1
0%700 mg
NCT01283516 · Phase 1
20%600 mg
NCT01283516 · Phase 1
0%500 mg
NCT01283516 · Phase 1
0%400 mg
NCT01283516 · Phase 1
0%300 mg
NCT01283516 · Phase 1
0%200 mg
NCT01283516 · Phase 1
0%100 mg
NCT01283516 · Phase 1
0%50 mg
NCT01283516 · Phase 1
15%
NCT02450903 · Phase 2 · registry result, not featured evidence
14.5%LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
8.6%750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
6.8%
NCT02040870 · Phase 1/2 · registry result, not featured evidence
—225 mgb
NCT01625234 · Phase 1/2
show 7 more results
—225 mg
NCT01625234 · Phase 1/2
—250 mg
NCT01625234 · Phase 1/2
—200 mg
NCT01625234 · Phase 1/2
—100 mg
NCT01625234 · Phase 1/2
—50 mg
NCT01625234 · Phase 1/2
—25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Serious AEs
49.2%a
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
—Ceritinib
NCT01828112 · Phase 3 · monotherapy
49.6%Ceritinib (On-treatment)
NCT01828112 · Phase 3
56.9%750 mg
NCT01283516 · Phase 1
60%700 mg
NCT01283516 · Phase 1
70%600 mg
NCT01283516 · Phase 1
40%500 mg
NCT01283516 · Phase 1
50%400 mg
NCT01283516 · Phase 1
33.3%300 mg
NCT01283516 · Phase 1
33.3%200 mg
NCT01283516 · Phase 1
50%100 mg
NCT01283516 · Phase 1
0%50 mg
NCT01283516 · Phase 1
45%
NCT02450903 · Phase 2 · registry result, not featured evidence
—LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
40.3%LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
47.9%750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
35%
NCT02040870 · Phase 1/2 · registry result, not featured evidence
50%225 mgb
NCT01625234 · Phase 1/2
show 7 more results
43.6%225 mg
NCT01625234 · Phase 1/2
50%250 mg
NCT01625234 · Phase 1/2
54.5%200 mg
NCT01625234 · Phase 1/2
40%100 mg
NCT01625234 · Phase 1/2
33.3%50 mg
NCT01625234 · Phase 1/2
25%25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 84.7%
nausea 68.8%
vomiting 67.2%
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 14 more results
diarrhoea 73%
nausea 63.5%
vomiting 53%
NCT01828112 · Phase 3
750 mg
diarrhoea 86.7%
nausea 84.3%
vomiting 62.4%
NCT01283516 · Phase 1
700 mg
nausea 100%
alanine aminotransferase increased 80%
diarrhoea 80%
NCT01283516 · Phase 1
600 mg
nausea 100%
diarrhoea 80%
fatigue 80%
NCT01283516 · Phase 1
500 mg
nausea 90%
diarrhoea 70%
dyspnoea 50%
NCT01283516 · Phase 1
400 mg
nausea 71.4%
diarrhoea 64.3%
vomiting 57.1%
NCT01283516 · Phase 1
300 mg
nausea 66.7%
abdominal pain 33.3%
anaemia 33.3%
NCT01283516 · Phase 1
200 mg
vomiting 100%
cough 66.7%
diarrhoea 66.7%
NCT01283516 · Phase 1
100 mg
asthenia 50%
axillary pain 50%
blood lactate dehydrogenase increased 50%
NCT01283516 · Phase 1
50 mg
dyspnoea 100%
blood lactate dehydrogenase increased 50%
bronchitis 50%
NCT01283516 · Phase 1
diarrhoea 85%
nausea 80%
vomiting 65%
NCT02450903 · Phase 2 · registry result, not featured evidence
diarrhoea 85.5%
nausea 78.2%
vomiting 71.8%
NCT01685138 · Phase 2 · registry result, not featured evidence
750 mg
diarrhoea 82.1%
nausea 82.1%
vomiting 65.7%
NCT01685060 · Phase 2 · registry result, not featured evidence
diarrhoea 74.8%
vomiting 61.2%
alanine aminotransferase increased 59.2%
NCT02040870 · Phase 1/2 · registry result, not featured evidence
225 mgb
gastrointestinal disorders 25%
nausea 25%
vomiting 25%
NCT01625234 · Phase 1/2
show 7 more results
225 mg
gastrointestinal disorders 60.6%
nausea 38.3%
vomiting 25.5%
NCT01625234 · Phase 1/2
250 mg
gastrointestinal disorders 50%
vomiting 50%
nausea 30%
NCT01625234 · Phase 1/2
200 mg
gastrointestinal disorders 54.5%
nausea 45.5%
vomiting 36.4%
NCT01625234 · Phase 1/2
100 mg
gastrointestinal disorders 40%
anaemia 20%
blood and lymphatic 20%
NCT01625234 · Phase 1/2
50 mg
gastrointestinal disorders 33.3%
nausea 33.3%
vomiting 33.3%
NCT01625234 · Phase 1/2
25 mg
anaemia 25%
blood and lymphatic 25%
blood creatinine increased 25%
NCT01625234 · Phase 1/2
200 mg
hypoalbuminaemia 100%
anaemia 50%
arthralgia 50%
NCT02898116 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 17 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ceritinib

PFS 16.6 vs 8.1 Chemotherapy months
time to event · months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
16.8 vs 7.2 Chemotherapy months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
5.4 vs 1.6 Chemotherapy months
NCT01828112 · Phase 3 · monotherapy
6.2 vs 1.6 Chemotherapy months
NCT01828112 · Phase 3 · monotherapy
Overall Survival 62.9 vs 40.7 Chemotherapy months
time to event · months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
17.7 vs 20.1 Chemotherapy months
NCT01828112 · Phase 3 · monotherapy
ORR 72.5% (n=189) vs 26.7% (n=187) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
73.5% (n=189) vs 33.2% (n=187) Chemotherapy
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
40.9% (n=115) vs 6.9% (n=116) Chemotherapy
NCT01828112 · Phase 3 · monotherapy
44.3% (n=115) vs 6.9% (n=116) Chemotherapy
NCT01828112 · Phase 3 · monotherapy
Duration of Response 23.9 vs 11.1 Chemotherapy months
time to event · months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
22.6 vs 9.8 Chemotherapy months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.6 vs 10.4 Chemotherapy months
NCT01828112 · Phase 3 · monotherapy
6.7 vs 8.3 Chemotherapy months
NCT01828112 · Phase 3 · monotherapy
Disease Control 84.7% (n=189) vs 73.8% (n=187) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
89.4% (n=189) vs 75.9% (n=187) Chemotherapy
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
76.5% (n=115) vs 37.9% (n=116) Chemotherapy
NCT01828112 · Phase 3 · monotherapy
80% (n=115) vs 39.7% (n=116) Chemotherapy
NCT01828112 · Phase 3 · monotherapy
Time to Response 1.42 vs 3.08 Chemotherapy months
time to event · months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.14 weeks as posted
show 3 more results
1.45 vs 2.93 Chemotherapy months*
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.29 weeks as posted
1.55 vs 2.22 Chemotherapy months*
NCT01828112 · Phase 3 · monotherapy · converted to months from 6.71 weeks as posted
1.48 vs 3.39 Chemotherapy months*
NCT01828112 · Phase 3 · monotherapy · converted to months from 6.43 weeks as posted
Intracranial 72.7% (n=22) vs 27.3% (n=22) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial Disease Control 86.4% (n=22) vs 90.9% (n=22) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial Duration of Response 16.6 vs NA Chemotherapy months
time to event · months
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 40.7% (n=140) @ 24wk750 mg
responder rate · % of participants
No placebo or comparator arm
NCT01685060 · Phase 2 · registry result, not featured evidence
show 8 more results
35.7% (n=140) @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
73.5% (n=83)
NCT01283516 · Phase 1
65.1% (n=83)
NCT01283516 · Phase 1
25% (n=20)
NCT02450903 · Phase 2 · registry result, not featured evidence
67.7% (n=124)
NCT01685138 · Phase 2 · registry result, not featured evidence
63.7% (n=124)
NCT01685138 · Phase 2 · registry result, not featured evidence
41.7% (n=103)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
32% (n=103)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Duration of Response 10.6 months @ 24wk750 mg
time to event · months
No placebo or comparator arm
NCT01685060 · Phase 2 · registry result, not featured evidence
show 8 more results
12.9 months @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
14.19 months
NCT01283516 · Phase 1
21.75 months
NCT01283516 · Phase 1
6.3 months
NCT02450903 · Phase 2 · registry result, not featured evidence
24 months
NCT01685138 · Phase 2 · registry result, not featured evidence
27.3 months
NCT01685138 · Phase 2 · registry result, not featured evidence
7.5 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
9.2 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
PFS 5.8 months @ 24wk750 mg
time to event · months
No placebo or comparator arm
NCT01685060 · Phase 2 · registry result, not featured evidence
show 6 more results
7.4 months @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
15.21 months
NCT01283516 · Phase 1
19.32 months
NCT01283516 · Phase 1
3.7 months
NCT02450903 · Phase 2 · registry result, not featured evidence
7.2 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
3.8 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

Ensartinib

ORR 42% (n=81) @ 78wk225 mg
event count · % of participants
No placebo or comparator arm
NCT01625234 · Phase 1/2 · converted to % from 34 participants as posted
Stable Disease 0% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
SD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Progressive Disease 100% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
PD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ceritinib's landscape · Ensartinib's landscape